What drove the significant increase in AbbVie's net revenues for the first half of 2026?

AbbVie's net revenues increased by 11.2% to $32.0 billion for the six months ended June 30, 2026. This growth was primarily fueled by strong performance in its Immunology portfolio, particularly Skyrizi and Rinvoq, which saw substantial year-over-year increases. The company also experienced growth in Neuroscience products like Vraylar and Botox Therapeutic, alongside contributions from other segments, offsetting declines in Humira due to biosimilar competition.

What is the strategic significance of the proposed acquisition of Apogee Therapeutics?

The proposed acquisition of Apogee Therapeutics for approximately $10.9 billion is a key strategic move for AbbVie. Apogee is focused on developing novel biologics for atopic dermatitis, asthma, and other inflammatory conditions. This acquisition is expected to enhance AbbVie's leading position in immunology by adding innovative pipeline assets and expanding its therapeutic reach in significant and growing markets.

How is the company managing the decline in Humira sales?

Humira's net revenues decreased by 37.2% for the six months ended June 30, 2026, primarily due to the ongoing impact of direct biosimilar competition following its loss of exclusivity. AbbVie is mitigating this decline through the strong performance of its newer growth drivers like Skyrizi and Rinvoq, which are effectively capturing market share and driving overall company growth, demonstrating the success of its portfolio diversification strategy.

What is the company's outlook on research and development and future growth drivers?

AbbVie maintains a strong commitment to R&D, with a pipeline of approximately 90 compounds, devices, or indications in development, many of which are in mid- to late-stage development. Key growth drivers include continued expansion of Skyrizi and Rinvoq, advancements in neuroscience, oncology, and aesthetics, and exploration of new areas like obesity. The acquisition of Apogee further underscores its strategy to invest in innovative therapies and expand its portfolio for long-term growth.

ABBV 10-Q Quarterly Report Q2 FY2026 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed August 3, 2026. Cited figures are marked; the original filing is the authoritative source.

AbbVie Inc. reported strong financial performance for the six months ended June 30, 2026, with net revenues reaching $32.0 billion^a, a 11.2% increase year-over-year.

This growth was primarily driven by robust sales in the Immunology segment, particularly Skyrizi and Rinvoq, which saw significant increases of 27.3% and 24.0% respectively. Operating earnings reached $10.4 billion^b, and diluted earnings per share (EPS) stood at $2.42, reflecting improved profitability and operational efficiency. The company also highlighted its ongoing commitment to R&D and strategic acquisitions, including the announced definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion, which aims to bolster its position in inflammatory conditions.

Despite the continued impact of Humira biosimilar competition, AbbVie's diversified portfolio and strong performance in key growth drivers demonstrate its resilience and strategic positioning for future growth. Cash flow from operations remained strong at $7.3 billion^c, supporting investments in the pipeline and shareholder returns.

02—Key points

Key Highlights

AbbVie reported a substantial 11.2% increase in net revenues to $32.0 billion for the first six months of 2026, driven by strong performance in its key growth areas.
The Immunology segment demonstrated impressive growth, with Skyrizi up 27.3% and Rinvoq up 24.0% year-over-year, showcasing continued market penetration and demand.
Diluted EPS reached $2.42 for the six months ended June 30, 2026, indicating improved profitability.
The company announced a significant agreement to acquire Apogee Therapeutics for approximately $10.9 billion, strengthening its pipeline in inflammatory diseases.
Operating earnings increased to $10.4 billion for the six-month period, reflecting effective cost management and revenue growth.
Cash flow from operating activities was robust at $7.3 billion for the six months ended June 30, 2026.
Despite biosimilar competition impacting Humira sales (down 37.2%), AbbVie's diversified revenue streams and pipeline development indicate a stable outlook.

03—Questions

Frequently Asked Questions

What drove the significant increase in AbbVie's net revenues for the first half of 2026?
AbbVie's net revenues increased by 11.2% to $32.0 billion for the six months ended June 30, 2026. This growth was primarily fueled by strong performance in its Immunology portfolio, particularly Skyrizi and Rinvoq, which saw substantial year-over-year increases. The company also experienced growth in Neuroscience products like Vraylar and Botox Therapeutic, alongside contributions from other segments, offsetting declines in Humira due to biosimilar competition.
What is the strategic significance of the proposed acquisition of Apogee Therapeutics?
The proposed acquisition of Apogee Therapeutics for approximately $10.9 billion is a key strategic move for AbbVie. Apogee is focused on developing novel biologics for atopic dermatitis, asthma, and other inflammatory conditions. This acquisition is expected to enhance AbbVie's leading position in immunology by adding innovative pipeline assets and expanding its therapeutic reach in significant and growing markets.
How is the company managing the decline in Humira sales?
Humira's net revenues decreased by 37.2% for the six months ended June 30, 2026, primarily due to the ongoing impact of direct biosimilar competition following its loss of exclusivity. AbbVie is mitigating this decline through the strong performance of its newer growth drivers like Skyrizi and Rinvoq, which are effectively capturing market share and driving overall company growth, demonstrating the success of its portfolio diversification strategy.
What is the company's outlook on research and development and future growth drivers?
AbbVie maintains a strong commitment to R&D, with a pipeline of approximately 90 compounds, devices, or indications in development, many of which are in mid- to late-stage development. Key growth drivers include continued expansion of Skyrizi and Rinvoq, advancements in neuroscience, oncology, and aesthetics, and exploration of new areas like obesity. The acquisition of Apogee further underscores its strategy to invest in innovative therapies and expand its portfolio for long-term growth.

04—Continue

← View all 10-Q filings